PolarityTE
- Company typePrivate
- Founded1998
- HeadquartersSalt Lake City, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PolarityTE does
PolarityTE, Inc., operating as PolarityBio, is a clinical-stage biotechnology company headquartered at 1960 South 4250 West, Salt Lake City, Utah, developing SkinTE, an investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process in chronic wounds and diabetic foot ulcers. SkinTE is produced from a patient's own healthy tissue; the resulting multicellular units are applied to the wound bed, where the company states they may engraft and serve as a cellular source that drives tissue repair activity. The company's lead program targets Wagner Grade 1 diabetic foot ulcers and is currently in Phase III clinical development at up to 20 US clinical sites enrolling up to 120 subjects, with interim results previously targeted for Q1 2025. The technology platform is protected by a USPTO patent granted in February 2021, and the company also maintains an FDA-cleared Expanded Access Program that allows qualified providers to administer SkinTE to eligible patients outside of the trial setting.
The business is pre-commercial: SkinTE has not been approved or cleared by the FDA, and the company has no disclosed product pricing or recurring revenue. The go-to-market model relies on direct engagement with clinical sites and wound-care specialists, with a planned future commercial channel through hospital pharmacies, wound care centers, and specialty clinics contingent on regulatory approval. The company emerged from a 2023 bankruptcy filing, during which financing had been disrupted by an alleged short-and-distort scheme, and has since rebranded as PolarityBio and recapitalized. Headcount is reported at 11–50 employees, and the capital structure as of the available data is supported by approximately $35.5 million of disclosed funding across March 2022 ($5.0M registered direct), June 2022 ($8.0M securities offering), and May 2024 ($12.5M equity plus a $10M senior credit facility from Avenue Venture Opportunities Fund). The addressable market is meaningful — roughly 7 million US chronic wound cases in 2023 and a bioengineered skin market projected at $4.88 billion by 2030 at a 12.3% CAGR — but the company currently captures none of it.
PolarityTE firmographics
Firmographics- Name
- PolarityTE
- Legal name
- PolarityTE, Inc.
- Website
- https://polarityte.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
PolarityTE industry classification
Industry- Product category
- Regenerative Medicine Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
- akta.pro secondary industries
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Care & Ulcer Management (HLAKACAN)
Keywords
Where PolarityTE is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PolarityTE business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Others
Revenue model
- SkinTE (investigational product): PolarityTE is a pre-commercial biotech company developing SkinTE, an autologous regenerative tissue product for chronic wound healing and diabetic foot ulcers. The company is in Phase III clinical trials with interim results expected Q1 2025. Revenue will be generated upon FDA approval through product sales to healthcare providers and hospitals.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
PolarityTE product offering
Product offeringCore offering
PolarityTE/PolarityBio develops SkinTE, an investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process by providing healthy cells and chemokines directly into the wound bed. The product is currently in Phase III clinical development for Wagner Grade 1 diabetic foot ulcers, supplemented by an FDA-cleared Expanded Access Program that provides eligible patients with investigational access.
Product overview
PolarityBio (formerly PolarityTE) is a biotechnology company developing SkinTE, an investigational autologous cutaneous multicellular biologic therapy. SkinTE is designed to initiate the wound healing process by providing healthy cells and chemokines in the wound bed for chronic wound healing and diabetic foot ulcers. The company operates through a single core product platform with clinical development programs advancing through Phase III trials, and maintains an FDA-cleared Expanded Access Program for eligible patients.
Differentiator
Problem solved
Functional benefit
Brands
- SkinTE®: Investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process for chronic wounds and diabetic foot ulcers.
Products and services
- SkinTE SkinTE is an investigational, autologous cutaneous multicellular therapy designed to initiate the wound healing process by providing healthy cells and chemokines in the wound bed. Following application, multicellular units may engraft and serve as a cellular source within the wound bed, supporting tissue repair cellular activity. It is currently in Phase III clinical development for Wagner Grade 1 diabetic foot ulcers and is also available to eligible patients under an FDA-cleared Expanded Access Program.
- FDA-cleared Expanded Access Program for SkinTE FDA-cleared program that enables selected healthcare providers to administer SkinTE to eligible patients with chronic wounds and diabetic foot ulcers prior to commercial approval, supporting investigational access and real-world data collection.
Companies that use PolarityTE
Customer profileSegments1 record
Ideal customer profiles1 record
PolarityTE technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PolarityTE partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights5 records
PolarityTE competitors and assessment
Company assessmentDirect peers
- Organogenesis Holdings: Organogenesis is the leading pure-play advanced wound care and regenerative medicine company, offering Apligraf and other skin substitutes for chronic wounds including diabetic foot ulcers and venous leg ulcers — directly competing with SkinTE in the same indication and customer base.
- MiMedx Group: MiMedx develops and commercializes amniotic membrane-based tissue grafts (e.g., EpiFix, AmnioFix) for chronic wound healing, including diabetic foot ulcers — a direct competitor to SkinTE in autologous/allogeneic regenerative wound therapy.
- Vericel Corporation: Vericel develops autologous cellular therapies including MACI (cartilage repair) and Epicel (burns), using patient-derived cell technology — closely comparable to PolarityBio's autologous cutaneous multicellular therapy platform and regenerative medicine business model.
Broad incumbents
- Smith+Nephew: Smith+Nephew's Advanced Wound Management division offers a comprehensive portfolio including skin substitutes, negative pressure wound therapy, and dressings — competing broadly with SkinTE across the chronic wound care continuum.
- Coloplast: Coloplast's Wound & Skin Care business offers advanced wound dressings and skin care products for chronic wounds including diabetic foot ulcers — a broad incumbent serving the same end customer base as PolarityBio's target market.
- 3M Health Care (KCI): 3M's KCI division (formerly Acelity) is a market leader in advanced wound care with V.A.C. negative pressure wound therapy systems and skin substitute products — competing with SkinTE for hospital wound care budgets.
- ConvaTec Group: ConvaTec is a major global wound care company offering advanced dressings, negative pressure wound therapy, and skin substitutes for chronic wounds — competing with SkinTE for hospital and wound clinic accounts.
- Integra LifeSciences: Integra LifeSciences offers Integra Dermal Regeneration Template and a broad wound care portfolio — a larger established incumbent with overlapping skin substitute and regenerative wound healing products competing with SkinTE.
Emerging players
- Celularity: Celularity develops placental-derived and cellular therapies for wound healing and regenerative medicine — an emerging player with biologically adjacent technology and overlapping target indications in chronic wound care.
- TissueTech: TissueTech develops and commercializes cryopreserved amniotic membrane and umbilical cord-based tissue grafts (e.g., AmnioGuard, Neox) for wound healing — an emerging competitor in regenerative wound care with overlapping indications to SkinTE.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
PolarityTE social profiles
Digital presencePolarityTE financial estimates
Financial estimateRevenue estimate
Valuation estimate
PolarityTE leadership team
Management profileNumber of profiles
Profiles11 records
PolarityTE funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PolarityTE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PolarityTE
What does PolarityTE do?
PolarityTE/PolarityBio develops SkinTE, an investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process by providing healthy cells and chemokines directly into the wound bed. The product is currently in Phase III clinical development for Wagner Grade 1 diabetic foot ulcers, supplemented by an FDA-cleared Expanded Access Program that provides eligible patients with investigational access.
Is PolarityTE a public or private company?
PolarityTE is a private company. It is classified as unknown and is currently operating.
When was PolarityTE founded?
PolarityTE was founded in 1998. It employs 11 to 50 people.
Where is PolarityTE based?
PolarityTE is headquartered in Salt Lake City, United States, in the North America region.
How does PolarityTE make money?
One revenue line is on record: skinTE (investigational product).
Who are PolarityTE's main competitors?
Direct peers on record are Organogenesis Holdings, MiMedx Group and Vericel Corporation. Broad incumbents are Smith+Nephew, Coloplast, 3M Health Care (KCI), ConvaTec Group and Integra LifeSciences. Emerging players are Celularity and TissueTech.
Does PolarityTE have an API?
No public API is recorded for PolarityTE.
What industry is PolarityTE in?
PolarityTE's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.